UMBC-UMB Partnership Symposium
RSVPs required - please RSVP at this link.
The goal of this annual event is to actively support establishing meaningful and sustainable research collaboration between our two institutions.
UMBC is comprised of the Colleges of Arts, Humanities and Social Sciences; Engineering and Information Technology; Natural and Mathematical Sciences; as well as the Erickson School and the School of Social Work.
UMB is comprised of the Schools of Dentistry, Medicine, Nursing, Law, Pharmacy and Social Work.
The research collaborations between UMBC and UMB build on four decades of meaningful partnership, which have led to substantial interactions:
• Shared Organizational Infrastructure
• Shared Research Facilities
• Dual Campus Degree Programs
• Research and Innovation Partnership Seed Grants
Sponsored by the Office of the Vice President for Research at UMBC and the Office of Research and Development at UMB, this Partnership Symposium is the next step in a growing relationship between our two institutions.To learn more about the partnership between UMBC and UMB, please see http://research.umbc.edu/umbc-umb-partnership.
Wendy Perrow is the CEO of AsclepiX Therapeutics and is responsible for managing the Company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as CEO of Alba Therapeutics.
Under her leadership, Alba Therapeutics completed a licensing agreement with Innovate Biopharmaceuticals, Inc. on February 29, 2016. The company conducted seven clinical trials in patients with Celiac Disease, completed the largest Phase IIb clinical trial in patients with celiac disease and validated the 1 st Celiac Disease Patient Reported Outcome (CeD PRO) with the lead compound Larazotide Acetate.
Prior to joining AscepiX, Ms. Perrow held senior executive positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with Rare and Orphan Diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global markets including Europe, Asia, and Latin America and U.S. At Merck, she held positions in marketing, marketing promotion, international business research analysis, training, and sales. A skilled marketer and business leader, she has led U.S. and Global launches/initiatives for Zocor®, Vasotec®, Varivax®, Cozaar® and Hyzaar®. Ms. Perrow began her career in a division of Johnson & Johnson.
Wendy received her MBA in International finance and marketing from The Fuqua School of Business at Duke University and received her bachelor’s degree from Eastern Illinois University. She is a member of the Duke Fuqua School of Business Alumni Board, Maryland Life Sciences Advisory Board, Maryland TEDCO Review Board, Healthcare Business Women's Association, and Women in Bio.
|8:30 am||Registration and Coffee|
|– Philip J. Rous, Provost, UMBC|
|– Bruce E. Jarrell, Chief Academic & Research Officer, UMB|
|9:10 am||Introduction of Keynote Speaker|
|– Jennifer Hammaker, Director, Maryland Innovation Initiative (MII)|
|9:15 am||Keynote: “Celiac Disease – A UMB Technology, From Pre-Clinical to Phase 3 Clinical Trials”|
|– Wendy Perrow, CEO, AsclepiX Therapeutics|
|10:15 am||Coffee Break and Poster Session|
|10:45 am||Research & Innovation Partnership Grant Updates|
|Moderator: Karl V. Steiner|
|Partnership Challenge Track|
|– Xudong Ge (UMBC) & Richard Pierson III (UMB-SOM)|
|– Chris Geddes (UMBC) & Colin Stine (UMB-SOM)|
|Partnership Seed Track|
|– Elsa Garcin (UMBC) & Patrick Wintrode (UMB-SOP)|
|– Soobum Lee (UMBC) & Mary Anne Melo (UMB-SOD)|
|– Christine Mair (UMBC) & Amanda Lehning (UMB-SSW)|
|11:45 am||Announcement of 2017/2018 Partnership Grant Teams|
|– Don Engel, Assistant Vice President for Research, UMBC|
|– Terry Rogers, Assistant Dean, Research Affairs, UMB-SOM|
|– Freeman A. Hrabowski III, President, UMBC|
|– Jay A. Perman, President, UMB|
|12:15 pm||Buffet Luncheon and Poster Session|
|1:30 pm||UMBC-UMB Partnership Symposium Concludes|